# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA703527 | Functional | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by change in tumor weight at 133 mg/kg (1,5,9qd treatment schedule) dosage | Mus musculus | 1 | ALA1123247 | organism-based format | Scientific Literature | |
2. | ALA879439 | Functional | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by change in tumor weight at 300 mg/kg (1 qd treatment schedule) dosage | Mus musculus | 2 | ALA1123247 | organism-based format | Scientific Literature | |
3. | ALA703530 | Functional | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by change in tumor weight at 80 mg/kg (1-5qd treatment schedule) dosage | Mus musculus | 1 | ALA1123247 | organism-based format | Scientific Literature | |
4. | ALA704401 | Functional | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by change in tumor weight at 300 mg/kg (treatment of 1qd schedule) dosage | Mus musculus | 2 | ALA1123247 | organism-based format | Scientific Literature | |
5. | ALA703943 | Functional | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by change in tumor weight at 40 mg/kg (treatment of 1-5qd schedule) dosage | Mus musculus | 1 | ALA1123247 | organism-based format | Scientific Literature | |
6. | ALA702727 | Functional | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by range in survival days at 133 mg/kg (1,5,9qd treatment schedule) dosage; Range is 15-22 | Mus musculus | 1 | ALA1123247 | organism-based format | Scientific Literature | |
7. | ALA702730 | Functional | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by range in survival days at 300 mg/kg (1 qd treatment schedule) dosage; Range is 19-23 | Mus musculus | 1 | ALA1123247 | organism-based format | Scientific Literature | |
8. | ALA701735 | Functional | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by range in survival days at 80 mg/kg (1-5qd treatment schedule) dosage; Range is 11-24 | Mus musculus | 1 | ALA1123247 | organism-based format | Scientific Literature | |
9. | ALA702181 | Functional | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by range in survival days at 300 mg/kg (treatment of 1qd schedule) dosage; Range is 14->45 | Mus musculus | 1 | ALA1123247 | organism-based format | Scientific Literature | |
10. | ALA702187 | Functional | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by range in survival days at 40 mg/kg (treatment of 1-5qd schedule) dosage; 24->45 | Mus musculus | 1 | ALA1123247 | organism-based format | Scientific Literature | |
11. | ALA708645 | Functional | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent increase in life span at 133 mg/kg (1,5,9qd treatment schedule) dosage | Mus musculus | 1 | ALA1123247 | organism-based format | Scientific Literature | |
12. | ALA708647 | Functional | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent increase in life span at 300 mg/kg (1 qd treatment schedule) dosage | Mus musculus | 2 | ALA1123247 | organism-based format | Scientific Literature | |
13. | ALA709277 | Functional | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent increase in life span at 80 mg/kg (1-5qd treatment schedule) dosage | Mus musculus | 1 | ALA1123247 | organism-based format | Scientific Literature | |
14. | ALA709284 | Functional | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by percent increase in life span at 300 mg/kg (treatment of 1qd schedule) dosage | Mus musculus | 2 | ALA1123247 | organism-based format | Scientific Literature | |
15. | ALA708742 | Functional | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by percent increase in life span at 40 mg/kg (treatment of 1-5qd schedule) dosage | Mus musculus | 1 | ALA1123247 | organism-based format | Scientific Literature | |
16. | ALA705241 | Functional | Antitumor activity against ic implanted L1210 lymphoid leukemia in mice expressed as active dose range (1,5,9qd treatment schedule) required to produce increase in life span by >25% was determined; Range 67-133 | Mus musculus | 1 | ALA1123247 | cell-based format | Scientific Literature | |
17. | ALA705243 | Functional | Antitumor activity against ic implanted L1210 lymphoid leukemia in mice expressed as active dose range (1-5qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 40-80 | Mus musculus | 1 | ALA1123247 | cell-based format | Scientific Literature | |
18. | ALA705246 | Functional | Antitumor activity against ic implanted L1210 lymphoid leukemia in mice expressed as active dose range (1 qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 200-400 | Mus musculus | 1 | ALA1123247 | cell-based format | Scientific Literature | |
19. | ALA705249 | Functional | Antitumor activity against ip implanted L1210 leukemia in mice expressed as active dose range (1-5qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 10-80 | Mus musculus | 1 | ALA1123247 | organism-based format | Scientific Literature | |
20. | ALA705255 | Functional | Antitumor activity against ip implanted L1210 leukemia in mice expressed as active dose range (1 qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 50-400 | Mus musculus | 1 | ALA1123247 | organism-based format | Scientific Literature |